Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease
The development of Simoa assays will be validated in a highly characterised control and Alzheimer cohort The Australian Imaging, Biomarker, and Lifestyle (AIBL) and a novel panel of the best 3 biomarkers established.
Authors
- Arne Ittner
- Kristie Stefanoska (ORCID: https://orcid.org/0000-0001-9322-9936)
- Prita R. Asih (ORCID: https://orcid.org/0000-0002-1973-9628)
- Kaj Blennow
- Juan Lantero Rodriguez
- EMS Bandara
- Ralph N Martins
- Henrik Zetterberg
- Steve Pedrini
Institutions
- Edith Cowan University (AU)
- Karolinska University Hospital (SE)
- University of Wisconsin–Madison (US)
- Flinders University (AU)
- Universitat Pompeu Fabra (ES)
- Hong Kong Science and Technology Parks Corporation (HK)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Sorbonne Université (FR)
- Institut de Myologie (FR)
- Pitié-Salpêtrière Hospital (FR)
- Australian Alzheimer’s Research Foundation (AU)
- National Hospital for Neurology and Neurosurgery (GB)
- Institut du Cerveau (FR)
- Dementia Australia (AU)
- University College London (GB)
- University of Gothenburg (SE)
- Macquarie University (AU)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108325
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00